Indian Journal of Nephrology

Rare, yet emerging cause of graft dysfunction - ALECT 2 Amyloidosis


0 Comments1 Minute

Association for Molecular Pathology 2018

Patterns of Deletion 13q Associated with other Abnormalities Detected by Fluorescence In Situ Hybridization (FISH) in Multiple Myeloma Patients – An Experience from A Referral…


0 Comments1 Minute

International Journal of Surgical Pathology

Myxoinflammatory Fibroblastic Sarcoma of Eyeball in an Infant: A Rare Presentation


0 Comments1 Minute

Edition 12

The FDA granted accelerated approval to Atezolizumab (Tecentriq) plus nanoparticle albumin-bound (nab) Paclitaxel (Abraxane) for unresectable locally advanced or metastatic PDL-1…


0 Comments2 Minutes

Edition 11

In a recent clinical trial, researchers have found promising clinical activity of Pembrolizumab with Trastuzumab in patients with PD-L1 positive, Trastuzumab-resistant, advanced…


0 Comments1 Minutes

Edition 10

In a recent clinical trial, researchers found that patients with a higher tumor mutational burden, T cell inflamed gene expression profile and PDL-1 expression showed a better…


0 Comments2 Minutes

Edition 09

The FDA approved Osimertinib (Tagrisso) for the first-line treatment of metastatic NSCLC with (EGFR) exon 19 deletions or exon 21 L858R mutations (Read More). The FDA approved…


0 Comments3 Minutes

Edition 08

The FDA granted approval to Gilteritinib for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation (Read more). The…


0 Comments3 Minutes

Edition 07

A prospective cohort study of 323 patients with metastatic NSCLC showed marked increase in detection of therapeutically targetable mutations and improved delivery of molecularly…


0 Comments2 Minutes

Edition 06

The targeted therapy Venetoclax (Venclexta) can now be used for a broader group of patients with chronic lymphocytic leukemia (CLL). The U.S. Food and Drug Administration (FDA)…


0 Comments2 Minutes